Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.42 |
| ▸ | CTSK | P43235 | 9/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.39 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6580234 | 0.90 | CTSL (0.49) | CTSLCAPN1CTSKCASP1CASP3 | |
| SCHEMBL6577721 | 0.87 | CTSL (0.47) | CTSLCAPN1CTSKCASP1CASP3 | |
| SCHEMBL6583598 | 0.85 | CTSL (0.51) | CTSLCAPN1CTSKCASP1CASP3 | |
| SCHEMBL6578118 | 0.84 | CTSK (0.51) | CTSLCAPN1CTSKCASP1CASP3 | |
| SCHEMBL6580531 | 0.81 | CAPN1 (0.41) | CAPN1CTSKCASP1CASP3TAOK1 | |
| SCHEMBL6582333 | 0.81 | PSMB8 (0.41) | CTSLCAPN1CTSKCTSS | |
| SCHEMBL6580295 | 0.80 | CTSK (0.60) | CTSLCTSKCTSS | |
| SCHEMBL6582257 | 0.79 | CASP3 (0.53) | CTSLCAPN1CTSKCASP1CASP3 | |
| SCHEMBL6578042 | 0.79 | CTSK (0.54) | CTSLCAPN1CTSKCASP1CASP3 | |
| SCHEMBL6583896 | 0.79 | CTSK (0.46) | CTSLCAPN1CTSKCASP1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180927-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2004-09-16 | — | — | US | disclosed |
| EP-0936912-B1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORP (US) | 2004-02-11 | — | — | EP | disclosed |
| US-20020128476-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180927-A1 | Inhibitors of cysteine protease | CTSK, CTSZ, CTSS | CTSL 7/4885CAPN1 81/4885CTSK 1/4885 |
| US-20020128476-A1 | Inhibitors of cysteine protease | CTRC, RCE1, CTRL | CTSL 8/4885CAPN1 178/4885CTSK 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.